ERYTECH Pharma S.A.
ERYP · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | -$0 | $3 | $9 | $8 |
| G&A Expenses | $3 | $4 | $2 | $5 |
| SG&A Expenses | $3 | $4 | $2 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$5 | -$1 | $0 | -$1 |
| Operating Expenses | -$3 | $6 | $12 | $13 |
| Operating Income | $3 | -$6 | $13 | -$13 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | $1 | $2 | $1 |
| Pre-Tax Income | $3 | -$5 | $15 | -$12 |
| Tax Expense | -$3 | $0 | $4 | -$1 |
| Net Income | $6 | -$5 | $11 | -$12 |
| % Margin | – | – | – | – |
| EPS | 0.19 | -0.17 | 0.35 | -0.38 |
| % Growth | 211.8% | -148.6% | 192.1% | – |
| EPS Diluted | 0.19 | -0.17 | 0.35 | -0.38 |
| Weighted Avg Shares Out | 31 | 31 | 31 | 31 |
| Weighted Avg Shares Out Dil | 31 | 31 | 31 | 31 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $4 | -$1 | $1 |
| Interest Expense | $0 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $4 | $2 | $1 |
| EBITDA | $4 | -$2 | $17 | -$11 |
| % Margin | – | – | – | – |